$NGEN News

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NervGen Pharma Increases Mixed Shelf Offering From $150M To $250M

Why Is NervGen Pharma Stock Gaining Tuesday?

NervGen Pharma Announces Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery With NVG-291 In The Phase 1B/2a CONNECT SCI Study; Notes 100% Of Subjects Were Classified As Responders Against 10% For Placebo

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

NervGen Announces Proposed Public Offering of Securities

NervGen Pharma Announces Commencement Of Public Offering Of Common Shares

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

HC Wainwright & Co. Initiates Coverage On NervGen Pharma with Buy Rating, Announces Price Target of $18

NervGen Pharma Appoints Keith Vendola CFO, Effective Immediately

NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

NervGen Pharma shares are trading higher after the company announced the completion of an End-of-Phase 2 meeting with the FDA and alignment on the company's Phase 3 registrational trial, RESTORE, to evaluate NVG-291 to treat chronic tetraplegia.

NervGen Pharma shares are trading higher after the company announced the completion of an End-of-Phase 2 meeting with the FDA and alignment on the company's Phase 3 registrational trial, RESTORE, to evaluate NVG-291 to treat chronic tetraplegia.

NervGen Pharma Completes End-Of-Phase 2 Meeting With FDA, Restores Phase 3 Registrational Trial To Evaluate NVG-291 To Treat Chronic Tetraplegia

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

NervGen Pharma Voluntarily Delisting From TSX Venture Exchange, Effective March 16

NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs